The disease is heterogeneous and comprises biologically distinct subtypes: hormone receptor–positive/HER2-negative (HR+/HER2−), HER2-positive (HER2+), and triple-negative breast cancer (TNBC). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.